Equillium, Inc. - EQ STOCK NEWS

Equillium, Inc. (Nasdaq: EQ) announced promising exploratory data from the EQUALISE study involving itolizumab for treating systemic lupus erythematosus (SLE). Patients without lupus nephritis but with elevated urine protein experienced significant reductions in UPCR, with a 33% and 42% decrease noted at Days 29 and 57, respectively. Additionally, patients with elevated albumin/creatinine ratios showed similar improvements. The company plans to amend the study to include newly diagnosed lupus nephritis patients and expects interim results by year-end, bolstered by FDA fast track designation for itolizumab.

Equillium (Nasdaq: EQ) reported positive financial and clinical developments for Q2 2021. Notably, positive results from the Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD) were highlighted, prompting plans to advance to a pivotal Phase 3 study. R&D expenses rose to $6.0 million from $3.9 million year-over-year, while net loss widened to $9.2 million, or $(0.31) per share, compared to $(0.37) per share last year. Cash reserves were $97.6 million, expected to fund operations into 2023.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, announced its participation in the BTIG Virtual Biotechnology Conference on August 9 & 10, 2021. CEO Bruce Steel and Dr. Dolca Thomas, EVP of R&D and CMO, will present a clinical overview and engage in a Fireside Chat with analyst Justin Zelin. The event is set for August 10, 2021, at 12 PM ET via a virtual webcast. Equillium is focused on developing itolizumab to address severe autoimmune and inflammatory disorders, including aGVHD, lupus, and asthma.

Equillium, Inc. (Nasdaq: EQ) has successfully completed an End-of-Phase 1 meeting with the FDA for itolizumab, targeting first-line treatment for acute graft-versus-host disease (aGVHD). This outcome paves the way for a pivotal Phase 3 study aimed at supporting a Biologics License Application (BLA). The study is set to begin in Q4 2021 and will compare itolizumab to standard high-dose corticosteroids, with complete response at Day 29 as the primary endpoint. Itolizumab has received FDA fast track and orphan drug designations.

Equillium, Inc. has announced promising topline results from the Phase 1b EQUATE study for its drug, itolizumab, targeting first-line acute graft-versus-host disease (aGVHD). In a cohort of 20 high-risk patients, the study reported a 55% complete response rate and a 70% overall response rate by Day 29. Patients experienced rapid, durable responses, leading to a significant 67% reduction in corticosteroid usage. The FDA has granted itolizumab fast track and orphan drug designations for aGVHD, with plans for pivotal studies ahead.

Equillium, Inc. (Nasdaq: EQ) announced a new assay for measuring CD6 engagement as a pharmacodynamic marker in autoimmune diseases at the CYTO Virtual Interactive Meeting. The assay, highlighted by Stephen Connelly, achieves up to 96% receptor occupancy in fresh T cells, aiding in optimizing dosages for itolizumab, a monoclonal antibody targeting CD6. This development supports ongoing clinical trials for conditions including graft-versus-host disease and lupus. The assay was developed in collaboration with Precision for Medicine.

Equillium, a clinical-stage biotechnology company, announced its participation in the JMP Securities Life Sciences Conference on June 16-17, 2021. CEO Bruce Steel will overview itolizumab’s mechanism and ongoing clinical programs, focusing on the EQUATE study data for acute graft-versus-host disease, which will be revealed on June 11, 2021, at EHA. Attendees can access a live webcast of the presentation on the company’s website. Equillium develops itolizumab for severe autoimmune and inflammatory disorders, addressing critical medical needs.

Equillium, Inc. (Nasdaq: EQ) announced a collaboration with the Kennedy Institute for Rheumatology and the University of Oxford to study itolizumab, a CD6 monoclonal antibody, for severe autoimmune disorders. This research will investigate how itolizumab influences T cell responses through the CD6-ALCAM pathway, crucial in rheumatic diseases. With less than 25% of rheumatoid arthritis patients achieving remission on standard treatments, this collaboration aims to develop novel therapeutic strategies. The study is expected to enhance the understanding of CD6 biology and improve treatment outcomes.

Equillium, Inc. (Nasdaq: EQ) will host a conference call on June 11, 2021, at 8:00 am ET to discuss topline data from the EQUATE study of itolizumab for treating acute graft-versus-host disease (aGVHD) at EHA2021 Virtual Congress. The conference will feature speakers like Dolca Thomas, M.D., Steve Connelly, Ph.D., and CEO Bruce Steel, followed by a Q&A session. The company emphasizes that the risk-benefit profile supports advancing itolizumab in first-line therapy for severe autoimmune disorders. A live webcast will be accessible on their website.